article
5 September 2018 | By Steven G Jarvis (Head of Pharma & Biotech Segment Strategy - MilliporeSigma)
Assessing targets that are unable – or rather, extremely difficult – to reach pharmacologically, has prevented researchers from achieving desired clinical successes, most notably in the realm of cancer research. However, many advances are being made to shedlight on these difficult yet desirable target areas.